Search results
Results From The WOW.Com Content Network
Lisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. [16]
Amphetamine [note 2] (contracted from alpha-methylphenethylamine) is a central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity; it is also used to treat binge eating disorder in the form of its inactive prodrug lisdexamfetamine.
Studies consistently show that most students report using stimulant medications, legally or illegally to improve academic performance, specifically to increase concentration, organization, and the ability to stay up longer and study. [32] The abuse of this drug has made prescribing it much more meticulous.
(Reuters) -The U.S. Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing ...
Dextroamphetamine (dexamfetamine, (D)-amphetamine), the drug's dextrorotatory enantiomer; Levoamphetamine (levamfetamine, (L)-amphetamine), the drug's levorotatory enantiomer; Adderall, a brand of mixed amphetamine salts; Lisdexamfetamine, a prodrug of dextroamphetamine marketed under the brand name Vyvanse
The Food and Drug Administration (FDA) approved the first generic versions of Vyvanse, a drug used to treat attention deficit/hyperactivity disorder (ADHD), a decision that comes amid a nationwide ...
Drugs in the class of amphetamines, or substituted amphetamines, are known to induce "amphetamine psychosis" typically when chronically abused or used in high doses. [8] In an Australian study of 309 active methamphetamine users, 18% had experienced a clinical level psychosis in the past year. [ 9 ]
The U.S. Food and Drug Administration had said on Monday it has approved generic versions of Vyvanse from 11 drugmakers after Takeda's exclusivity over the drug expired on Aug. 24.